At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Imprime PGG +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Imprime PGG and Rituximab for Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsHiberCell, Inc.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartDec 2014
Primary CompletionJul 2019
Study CompletionFeb 2021
TodayJul 2026
First PostedMar 13, 2014
Enrollment StartDec 1, 2014
Primary CompletionJul 11, 2019
Study CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 12.3 years ago
Interventions
Imprime PGGdrug
Rituximabdrug